2Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma, 2011,52: 2270-2275.
3Bernstein SH, Unger JM, Leblanc M, et al. Natural history of CNS relapse in patients with aggressive non-Hodgkin lymphoma: a 20-year follow up analysis of SWOG 8516-The Southwest Oncology Group. J Clin Oncol, 2009, 27:114-119.
4Villa D, Connors JM, Shenkier TN, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol, 2010, 21: 1046-1052.
5Papageorgiou SG, Diamantopoulos P, Levidou G, et al. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without rituximab. Hematol Oncol, 2012 May 18. doi: 10.1002/hon.2012.
6Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post- rituximab. Ann Hematol, 2011, 90:809-818.
7Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood, 2005, 105: 496-502.
8Kridel R, Dietrich PY. Prevention of CNS relapse in diffuse large B- cell lymphoma. Lancet Oncol, 2011, 12: 1258-1266.
9Kumar A, Vanderplas A, Lacasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer, 2012, 118: 2944-2951.
10Baraniskin A, Deckert M, Schulte-Ahedorneburg G, et al. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br J Haematol, 2012, 156: 421-432.
